GSK plc (GSK)
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It also focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases; and strategic research collaboration with Engitix Ltd. to identify and validate novel therapeutic targets driving liver fibrosis regression. The company has a strategic alliance with AN2 Therapeutics, Inc. for the development of new therapies for TB. GSK plc was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. The company was founded in 1715 and is headquartered in London, United Kingdom.
- Ticker
- GSK
- Exchange
- NYSE
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- 52-week range
- $45.81 - $61.70
Valuation
- Share price
- $50.33 (close of Nov 6, 2026)
- P/E (TTM)
- 17.27x
- Price to book
- 4.08x
- Price to free cash flow
- 10.10x
Price performance
| Period | Change |
|---|---|
| 1 day | -0.16% |
| 5 days | +1.66% |
| 1 month | +8.00% |
| 3 months | -3.53% |
| 6 months | -0.40% |
| Year to date | +2.63% |
| 1 year | +6.86% |
| 3 years | +44.67% |
| 5 years | +15.73% |
| 10 years | +30.29% |
| All time | +7,952.80% |
Short interest
- As of
- Oct 15, 2026
- Short % of float
- 0.73%
- Shares short
- 14.58M
- Days to cover
- 2.14
- Change since prior report
- -1.47%
- Source
- FINRA consolidated short interest
Members of Congress who disclosed GSK trades
Lisa McClain · Bruce Westerman · Val Hoyle · Robert Aderholt
Super investors holding GSK
Dodge & Cox (Dodge & Cox Funds) · Ray Dalio (Bridgewater Associates) · Kahn Brothers (Kahn Brothers Group) · Ken Griffin (Citadel) · Hillman Capital (Hillman Capital Management, Inc) · Tweedy Browne (Tweedy Browne Company LLC) · Richard Pzena (Pzena Investment Management) · Sarah Ketterer (Causeway Capital Management LLC)
Profitability and growth
- Return on equity
- 35.82%
- Return on invested capital
- 20.25%
- Return on assets
- 9.35%
- Return on capital employed
- 19.97%
- Gross margin
- 72.40%
- Net margin
- 17.50%
- EBITDA margin
- 31.36%
- Revenue growth
- 4.11%
- Net income growth
- 121.98%
- Free cash flow growth
- 24.02%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- 9.90%
- Current ratio
- 0.86x
- Net debt to EBITDA
- 1.38x
Latest reported year
- Period end
- Dec 31, 2025
- Fiscal year
- 2025
- Shares outstanding
- 2.03B
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|---|---|---|---|
| 2025-12-31 | 72.40% | 17.50% | 35.82% | 20.25% |
| 2024-12-31 | 71.16% | 8.21% | 19.68% | 11.62% |
| 2023-12-31 | 71.76% | 16.25% | 38.52% | 19.44% |
| 2022-12-31 | 67.42% | 51.00% | 148.14% | 18.42% |
| 2021-12-31 | 66.95% | 17.76% | 20.55% | 9.19% |
| 2020-12-31 | 67.44% | 23.61% | 27.63% | 12.05% |
| 2019-12-31 | 64.85% | 13.76% | 25.30% | 12.24% |
| 2018-12-31 | 66.77% | 11.75% | 98.67% | 15.89% |
| 2017-12-31 | 65.74% | 5.08% | 43.91% | 13.27% |
| 2016-12-31 | 66.69% | 3.27% | 18.38% | 7.25% |
Investor relations
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|---|---|
| 2026-10-28 | Sep 2026 | - |
| 2026-07-28 | Jun 2026 | - |
| 2026-04-29 | Mar 2026 | - |
| 2026-02-04 | Dec 2025 | - |
| 2025-10-29 | Sep 2025 | - |
| 2025-07-30 | Jun 2025 | - |
| 2025-04-30 | Mar 2025 | - |
| 2025-02-05 | Dec 2024 | - |
Filings and sources
- Company website
- gsk.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Novo Nordisk A S (NVO) · Organon & Co. (OGN) · Biogen Inc. (BIIB) · Bristol Myers Squibb Co (BMY) · Pfizer Inc (PFE) · Gilead Sciences, Inc. (GILD) · Amgen Inc (AMGN) · AstraZeneca plc (AZN)
Understanding these figures
Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades